In this module, Rowena Schwartz PharmD, BCOP, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair, will provide current data for treating patients with biosimilars in the era of the COVID-19 pandemic. The expert faculty will highlight the evolving impact of COVID-19 on healthcare expenditure, including availability of services and financial burdens. Therapeutic considerations amidst the pandemic will be relayed, along with resources for both patients and clinicians. At the conclusion of this 30-minute interview segment, learners will be provided current information for optimally administering biosimilar agents during the COVID-19 pandemic.
Healthcare professionals that treat inflammatory conditions, including gastroenterologists, rheumatologists, primary care practitioners, nurse practitioners, pharmacists and physician assistants
- Implement guidelines concerning COVID-19 and biosimilar agents into treatment approaches to improve patient care during the COVID-19 pandemic
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Beth Faiman PhD, RN, MSN, CNP, AOCN, FAAN||Consultant/Advisor: Bristol-Myers Squibb Company; GlaxoSmithKline plc; Karyopharm Therapeutics; Sanofi|
|Rowena Schwartz PharmD, BCOP||Consultant/Advisor: Merck & Co., Inc|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin, Emma Boring and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 Credits TM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider Number P0491).
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-018-H04-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Pfizer Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].